Tenecteplase for acute ischaemic stroke
- PMID: 35779556
- DOI: 10.1016/S0140-6736(22)01107-2
Tenecteplase for acute ischaemic stroke
Conflict of interest statement
ECS is on the steering committee of the NOR-TEST 2 trial and has received speaker honoraria from Boston Scientific unrelated to the present work. GT is on the adjudication committee of the BI 1123-0040 trial (a phase 3, multicentre, prospective, randomised, open-label, blinded endpoint [PROBE], active-controlled parallel group trial to assess the efficacy and safety of tenecteplase versus alteplase in Chinese patients with acute ischaemic stroke within 4·5 h after stroke onset).
Comment on
-
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29. Lancet. 2022. PMID: 35779553 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical